Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(5 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

University of Cincinnati, Cincinnati, Ohio

TriStar Bone Marrow Transplant, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson Cancer Center, Seattle, Washington